Is Trident Lifeline overvalued or undervalued?

As of 4 August 2025, Trident Lifeline's valuation grade has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 19.72, an EV to EBITDA of 15.00, and a PEG ratio of 0.23, which suggests that while the growth potential is reflected in the low PEG, the overall valuation remains high relative to earnings.
In comparison to peers, Trident Lifeline's PE ratio is significantly lower than Sun Pharma's 34.25 and Divi's Lab's 78.73, both of which are categorized as very expensive. However, it is also higher than more attractively valued companies like Dr. Reddy's Labs, which has a PE of 17.95, and Aurobindo Pharma at 18.29. The recent stock performance shows a decline of 6.3% over the past year, contrasting with a minimal increase in the Sensex, reinforcing the notion that Trident Lifeline is not currently a favorable investment.